187 related articles for article (PubMed ID: 38413979)
21. Characterization of kinase gene expression and splicing profile in prostate cancer with RNA-Seq data.
Feng H; Li T; Zhang X
BMC Genomics; 2018 Aug; 19(Suppl 6):564. PubMed ID: 30367578
[TBL] [Abstract][Full Text] [Related]
22. Cancer-Associated Perturbations in Alternative Pre-messenger RNA Splicing.
Shkreta L; Bell B; Revil T; Venables JP; Prinos P; Elela SA; Chabot B
Cancer Treat Res; 2013; 158():41-94. PubMed ID: 24222354
[TBL] [Abstract][Full Text] [Related]
23. Splicing modulation sensitizes chronic lymphocytic leukemia cells to venetoclax by remodeling mitochondrial apoptotic dependencies.
Ten Hacken E; Valentin R; Regis FFD; Sun J; Yin S; Werner L; Deng J; Gruber M; Wong J; Zheng M; Gill AL; Seiler M; Smith P; Thomas M; Buonamici S; Ghia EM; Kim E; Rassenti LZ; Burger JA; Kipps TJ; Meyerson ML; Bachireddy P; Wang L; Reed R; Neuberg D; Carrasco RD; Brooks AN; Letai A; Davids MS; Wu CJ
JCI Insight; 2018 Oct; 3(19):. PubMed ID: 30282833
[TBL] [Abstract][Full Text] [Related]
24. A bioinformatics-based functional analysis shows that the specifically androgen-regulated gene SARG contains an active direct repeat androgen response element in the first intron.
Steketee K; Ziel-van der Made AC; van der Korput HA; Houtsmuller AB; Trapman J
J Mol Endocrinol; 2004 Oct; 33(2):477-91. PubMed ID: 15525603
[TBL] [Abstract][Full Text] [Related]
25. Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferation.
Marrocco DL; Tilley WD; Bianco-Miotto T; Evdokiou A; Scher HI; Rifkind RA; Marks PA; Richon VM; Butler LM
Mol Cancer Ther; 2007 Jan; 6(1):51-60. PubMed ID: 17218635
[TBL] [Abstract][Full Text] [Related]
26. Autoregulation of the human splice factor kinase CLK1 through exon skipping and intron retention.
Uzor S; Zorzou P; Bowler E; Porazinski S; Wilson I; Ladomery M
Gene; 2018 Sep; 670():46-54. PubMed ID: 29802995
[TBL] [Abstract][Full Text] [Related]
27. Tumor suppressor role of RBM22 in prostate cancer acting as a dual-factor regulating alternative splicing and transcription of key oncogenic genes.
Jiménez-Vacas JM; Montero-Hidalgo AJ; Gómez-Gómez E; Sáez-Martínez P; Fuentes-Fayos AC; Closa A; González-Serrano T; Martínez-López A; Sánchez-Sánchez R; López-Casas PP; Sarmento-Cabral A; Olmos D; Eyras E; Castaño JP; Gahete MD; Luque RM
Transl Res; 2023 Mar; 253():68-79. PubMed ID: 36089245
[TBL] [Abstract][Full Text] [Related]
28. Androgen sensitivity related proteins in hormone-sensitive and hormone-insensitive prostate cancer cell lines treated by androgen antagonist bicalutamide.
Madarová J; Lukesová M; Hlobilková A; Riháková P; Murray PG; Student V; Vojtsek B; Kolár Z
Neoplasma; 2001; 48(5):419-24. PubMed ID: 11845989
[TBL] [Abstract][Full Text] [Related]
29. Broad variation in response of individual introns to splicing inhibitors in a humanized yeast strain.
Hunter O; Talkish J; Quick-Cleveland J; Igel H; Tan A; Kuersten S; Katzman S; Donohue JP; S Jurica M; Ares M
RNA; 2024 Jan; 30(2):149-170. PubMed ID: 38071476
[TBL] [Abstract][Full Text] [Related]
30. Biological validation that SF3b is a target of the antitumor macrolide pladienolide.
Yokoi A; Kotake Y; Takahashi K; Kadowaki T; Matsumoto Y; Minoshima Y; Sugi NH; Sagane K; Hamaguchi M; Iwata M; Mizui Y
FEBS J; 2011 Dec; 278(24):4870-80. PubMed ID: 21981285
[TBL] [Abstract][Full Text] [Related]
31. AT-101 (R-(-)-gossypol acetic acid) enhances the effectiveness of androgen deprivation therapy in the VCaP prostate cancer model.
McGregor N; Patel L; Craig M; Weidner S; Wang S; Pienta KJ
J Cell Biochem; 2010 Aug; 110(5):1187-94. PubMed ID: 20589722
[TBL] [Abstract][Full Text] [Related]
32. CDK12/13 promote splicing of proximal introns by enhancing the interaction between RNA polymerase II and the splicing factor SF3B1.
Panzeri V; Pieraccioli M; Cesari E; de la Grange P; Sette C
Nucleic Acids Res; 2023 Jun; 51(11):5512-5526. PubMed ID: 37026485
[TBL] [Abstract][Full Text] [Related]
33. AR intragenic deletions linked to androgen receptor splice variant expression and activity in models of prostate cancer progression.
Li Y; Hwang TH; Oseth LA; Hauge A; Vessella RL; Schmechel SC; Hirsch B; Beckman KB; Silverstein KA; Dehm SM
Oncogene; 2012 Nov; 31(45):4759-67. PubMed ID: 22266865
[TBL] [Abstract][Full Text] [Related]
34. Alternative splicing regulation by the androgen receptor in prostate cancer cells.
Germain L; Lafront C; Beaudette J; Karthik Poluri RT; Weidmann C; Audet-Walsh É
J Steroid Biochem Mol Biol; 2020 Sep; 202():105710. PubMed ID: 32534106
[TBL] [Abstract][Full Text] [Related]
35. Dysregulation of the splicing machinery is directly associated to aggressiveness of prostate cancer.
Jiménez-Vacas JM; Herrero-Aguayo V; Montero-Hidalgo AJ; Gómez-Gómez E; Fuentes-Fayos AC; León-González AJ; Sáez-Martínez P; Alors-Pérez E; Pedraza-Arévalo S; González-Serrano T; Reyes O; Martínez-López A; Sánchez-Sánchez R; Ventura S; Yubero-Serrano EM; Requena-Tapia MJ; Castaño JP; Gahete MD; Luque RM
EBioMedicine; 2020 Jan; 51():102547. PubMed ID: 31902674
[TBL] [Abstract][Full Text] [Related]
36. Inter-related in vitro effects of androgens, fatty acids and oxidative stress in prostate cancer: a mechanistic model supporting prevention strategies.
Lin H; Lu JP; Laflamme P; Qiao S; Shayegan B; Bryskin I; Monardo L; Wilson BC; Singh G; Pinthus JH
Int J Oncol; 2010 Oct; 37(4):761-6. PubMed ID: 20811696
[TBL] [Abstract][Full Text] [Related]
37. Difference in protein expression profile and chemotherapy drugs response of different progression stages of LNCaP sublines and other human prostate cancer cells.
Lin HP; Lin CY; Hsiao PH; Wang HD; Jiang SS; Hsu JM; Jim WT; Chen M; Kung HJ; Chuu CP
PLoS One; 2013; 8(12):e82625. PubMed ID: 24349321
[TBL] [Abstract][Full Text] [Related]
38. Complex impacts of PI3K/AKT inhibitors to androgen receptor gene expression in prostate cancer cells.
Liu L; Dong X
PLoS One; 2014; 9(10):e108780. PubMed ID: 25360799
[TBL] [Abstract][Full Text] [Related]
39. CYCLIN K down-regulation induces androgen receptor gene intronic polyadenylation, variant expression and PARP inhibitor vulnerability in castration-resistant prostate cancer.
Sun R; Wei T; Ding D; Zhang J; Chen S; He HH; Wang L; Huang H
Proc Natl Acad Sci U S A; 2022 Sep; 119(39):e2205509119. PubMed ID: 36129942
[TBL] [Abstract][Full Text] [Related]
40. Androgens up-regulate the insulin-like growth factor-I receptor in prostate cancer cells.
Pandini G; Mineo R; Frasca F; Roberts CT; Marcelli M; Vigneri R; Belfiore A
Cancer Res; 2005 Mar; 65(5):1849-57. PubMed ID: 15753383
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
